Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte-activating moiety.

The invention relates to a composition for the topical treatment and care of psoriatic skin. It consists exclusively of natural substances and comprises at the most peanut oil, olive oil, castor oil, avocado oil, rose oil, rose hydrolate, lanolin and phytosterol in the form of a mixture of at least peanut oil, olive oil, castor oil and lanolin.

Disclosed is an iontophoresis-based patch type medicine absorption device for allowing a medicine for medical treatment or a functional substance for skin care to be effectively absorbed into a user's skin by causing iontophoresis on the user's skin through a conductive patch. The iontophoresis-based patch type medicine absorption device for allowing the medicine for medical treatment or the functional substance for the skin care to be absorbed into the user's skin by the iontophoresis includes a medicine absorption device body that generates power to cause the iontophoresis. The medicine absorption device body includes a power circuit that is provided in an interior space of a body and that includes a power unit that generates the power for the iontophoresis and one or more electrodes to which the power is applied, and a bridge that is provided so as to be combinable with the body and that receives the power through the one or more electrodes. The bridge includes a bridge body provided so as to be combinable with the body and a plurality of bridge legs arranged along a circumferential direction of the bridge body and formed of a conductive material.

Transdermal medicaments containing cannabidiol (CBD) for use in the amelioration of conditions, including anxiety, depression, pain, inflammation, epilepsy, parkinson's disease, oxidative injury and nausea; and a method for preparing same.

The present disclosure relates to a method of preparing a thin film composite layer immobilizing vesicles incorporating a transmembrane protein on a porous substrate membrane, comprising providing an aqueous solution comprising the vesicles and a di-amine or tri-amine compound, covering the surface of a porous support membrane with the aqueous solution, applying a hydrophobic solution comprising an acyl halide compound, and allowing the aqueous solution and the hydrophobic solution to perform an interfacial polymerization reaction to form the thin film composite layer.

To provide a transdermal drug delivery patch that can be suitably used for an immediate release application of a pharmaceutical with a comparatively low molecular weight. A transdermal drug delivery patch, provided with a matrix and at least one drug disposed within the matrix, wherein the matrix has a water holding capacity of 10 mg/cm.sup.2 or less, and the drug is a pharmaceutical having a molecular weight of 5000 or less.

The present invention is directed to therapeutic pharmaceutical compositions of 1-Methyl-2′, 6′-pipecoloxylidide or it pharmaceutically acceptable salts for application to the skin and the use thereof.

A novel device and method for delivering a liquid containing an active ingredient to a treatment site on the skin is disclosed. The device is useful for treating lesions or abnormal skin features such as corns, warts, calluses, bunions, actinic keratoses and hard hyperkeratotic skin as is often found on the face, arms, legs or feet.

Disclosed herein compositions of polysaccharides chemically cross-linked by aromatic dialdehydes. The compositions may be in form of polymeric sheets for a variety of applications. Disclosed also nano-sized particles comprising the polysaccharide chemically cross-linked by aromatic dialdehydes. The nano-sized particles may further comprise lipids and surfactants. Intranasal delivery of the nano-sized particles enables delivery of biologically active agents into the brain. Topical and transdermal delivery of the nano-sized particles enables delivery of biologically active agents for treatment of systemic or dermatological disorders. Methods of manufacturing and uses of the compositions are also disclosed.

The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof, the adhesive agent layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and/or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinylpyrrolidone, and in the adhesive agent layer, a mass ratio of a content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form and a content of the cross-linked polyvinylpyrrolidone (content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form:content of the cross-linked polyvinylpyrrolidone) is 10:3 to 1:3.